Press release Communiqué de presse

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter

Press release Communiqué de presse

December 18, 2020 18 December, 2020

Sernova to Present at H.C. Wainwright BioConnect 2021 Conference

December 18, 2020 - 9:00 a.m. EST

LONDON, ONTARIO – December 18, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a leading clinical-stage regenerative medicine therapeutics company, today announces that Dr. Philip Toleikis, President and CEO of Sernova will present at the H.C. Wainwright BioConnect 2021 Conference taking place virtually January 11-14.

Dr. Toleikis is scheduled to host a virtual presentation that will be available on demand during the conference, starting at 6:00 AM EST on Monday January 11, 2021. Sernova’s management team will also participate in one-on-one meetings at the conference.

H.C. Wainwright BioConnect 2021 Conference

Date: Monday, January 11, 2021 to Thursday, January 14, 2021

Time: On demand


For more information on the H.C. Wainwright BioConnect 2021 Conference or to schedule one-on-one meetings with management, please contact your H.C. Wainwright representative.


Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells, and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit

For further information contact: Dominic Gray Sernova Corp Tel: (519) 858-5126